Tankova, T.; Senkus, E.; Beloyartseva, M.; Borštnar, S.; Catrinoiu, D.; Frolova, M.; Hegmane, A.; Janež, A.; Krnić, M.; Lengyel, Z.;
et al. Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer. Cancers 2022, 14, 1598.
https://doi.org/10.3390/cancers14071598
AMA Style
Tankova T, Senkus E, Beloyartseva M, Borštnar S, Catrinoiu D, Frolova M, Hegmane A, Janež A, Krnić M, Lengyel Z,
et al. Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer. Cancers. 2022; 14(7):1598.
https://doi.org/10.3390/cancers14071598
Chicago/Turabian Style
Tankova, Tsvetalina, Elżbieta Senkus, Maria Beloyartseva, Simona Borštnar, Doina Catrinoiu, Mona Frolova, Alinta Hegmane, Andrej Janež, Mladen Krnić, Zoltan Lengyel,
and et al. 2022. "Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer" Cancers 14, no. 7: 1598.
https://doi.org/10.3390/cancers14071598
APA Style
Tankova, T., Senkus, E., Beloyartseva, M., Borštnar, S., Catrinoiu, D., Frolova, M., Hegmane, A., Janež, A., Krnić, M., Lengyel, Z., Marcou, Y., Mazilu, L., Mrinakova, B., Percik, R., Petrakova, K., Rubovszky, G., Tokar, M., & Vrdoljak, E.
(2022). Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer. Cancers, 14(7), 1598.
https://doi.org/10.3390/cancers14071598
